| Document |
Document Title |
|
WO/2022/029068A1 |
The present invention relates to compounds of formula (I), (I), wherein R1, R2, R3, R4 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the c...
|
|
WO/2022/028572A1 |
This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
|
|
WO/2022/028527A1 |
A piperidine-containing heterocyclic compound represented by formula (I). The compound treats illnesses and diseases related to complement alternative pathway activation by inhibiting/regulating a complement factor B.
|
|
WO/2022/028507A1 |
A heterocyclic compound as represented by formula I, a preparation method therefor, a pharmaceutical composition comprising same and use thereof. The heterocyclic compound can be used as a complement factor B inhibitor, and is used for p...
|
|
WO/2022/022600A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2022/025648A1 |
The present invention provides a compound for a capping layer and an organic light-emitting device comprising same.
|
|
WO/2022/022221A1 |
The present invention relates to the technical field of pesticides and acaricides, and in particular to an isoxazoline-substituted benzamide derivative, and a preparation method therefor and use thereof. Specifically provided is a compou...
|
|
WO/2022/025174A1 |
The present invention addresses the problem of providing: a compound useful as an antitumor agent; an intermediate thereof; and a pharmaceutical composition, an antitumor agent, and a dihydroorotic acid dehydrogenase inhibitor containing...
|
|
WO/2022/025647A1 |
The present invention provides: a compound, represented by formula 1, for a capping layer; and an organic light-emitting device including a first electrode, a second electrode, at least a single organic material layer interposed between ...
|
|
WO/2022/026892A1 |
Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention ar...
|
|
WO/2022/022616A1 |
The present invention relates to 2,4,4-trisubstituted dihydrooxazole derivatives and preparation methods therefor and the use thereof, belonging to the technical field of pharmaceutical synthesis. Specifically, the present invention rela...
|
|
WO/2022/017442A1 |
Disclosed are a bifunctional protein degradation-targeted chimera compound, a preparation method therefor and medicinal use thereof. In particular, the present invention relates to a compound as shown by general formula (I), a preparatio...
|
|
WO/2022/017533A1 |
The present invention relates to a compound useful as a CDK7 kinase inhibitor and use thereof. Specifically, the compound of the present invention has a structure shown in formula I, wherein the definition of each group and substituent i...
|
|
WO/2022/017836A1 |
The present invention relates to fungicidal compositions comprising, as active components, (R)- 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1,2,4-t
riazol-1-yl)propan-2-ol (I) and N-(2- fluorophenyl)-4-[5-(trifluoromethyl)-1,2,4...
|
|
WO/2022/017444A1 |
a compound (as represented by formula I) serving as an Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor, as well as a pharmaceutical composition thereof, a preparation method therefor, and a use in treatin...
|
|
WO/2022/020730A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/016490A1 |
The present invention provides processes for making enatiomerically pure lotilaner characterized by improving the enantiomeric purity of 3-methyl-5-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethy
l)-4H-isoxazol-3-yl]thiophene-2-carboxy...
|
|
WO/2022/020585A1 |
The present disclosure provides processes for making enantiomerically pure isoxazoline compounds of formula (1), (1). The present disclosure also provides processes for making enantiomerically pure isoxazoline compounds of formula (1) ch...
|
|
WO/2022/018105A1 |
The invention provides novel compounds having the general formula I wherein R and X are as defined herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/020342A1 |
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
|
|
WO/2022/017371A1 |
A heterocyclic compound represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, and a use thereof as a dual inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ) and phosphatidylinositol ...
|
|
WO/2022/018182A1 |
The invention relates to a light emitting organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has - one first chemical moiety with a structure of formula I, and ...
|
|
WO/2022/015624A1 |
This present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I) and ph...
|
|
WO/2022/015977A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/013408A2 |
The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceuti...
|
|
WO/2022/015975A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/013728A1 |
The present invention relates to a novel compound having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutica...
|
|
WO/2022/015051A1 |
The present invention relates to an aryl or heteroaryl derivative and a pharmaceutical composition comprising same as an active ingredient for treatment of kinase-related disease. An aryl or heteroaryl derivative provided according to an...
|
|
WO/2022/015979A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/013378A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such...
|
|
WO/2022/015957A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/015938A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/007462A1 |
Disclosed in the present invention is an immunomodulator, specifically relating to a compound that inhibits IL-17A and the use thereof as an immunomodulator in the preparation of a drug. Disclosed in the present invention is the use of a...
|
|
WO/2022/008475A1 |
The present invention relates to indole derivatives of formula (I') as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preve...
|
|
WO/2022/007909A1 |
The present application relates to the technical field of organic material and provides a nitrogen-containing compound, an electronic component and an electronic device. The nitrogen-containing compound has a structure as shown in formul...
|
|
WO/2022/009044A1 |
The invention relates to a process for preparing immediate precursors for pyroxasulfone and fenoxasulfone preparation of the formula (I). The process comprises a bromination reaction of a benzylic position without light irradiation (step...
|
|
WO/2022/007979A1 |
Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefo...
|
|
WO/2022/008426A1 |
The present invention relates to a combination of selective blockers of TASK- 1 and TASK-3 channels, in particular substituted imidazo [ 1,2-a]pyrimidine and substituted imidazo [ 1,2-a]pyridine derivatives of formula (II) and α2 -Adren...
|
|
WO/2022/008383A1 |
The present invention discloses compounds according to Formula (I) wherein R1, R2, R3, L1, L2, and L3 are as defined herein. The present invention relates to compounds inhibiting discoidin domain receptors (DDRs), methods for their produ...
|
|
WO/2022/011083A1 |
The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart...
|
|
WO/2022/011084A1 |
The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...
|
|
WO/2022/007461A1 |
Disclosed is an immunomodulator, and the present invention specifically relates to a compound for inhibiting IL-17A and an application of the compound serving as the immunomodulator in the preparation of a drug. Disclosed is an applicati...
|
|
WO/2022/003610A1 |
The present invention discloses an isoxazoline compound of formula (I), Formula (I) wherein, R1, R3, Cy, A, D, p and q are as defined in the detailed description. The present invention further discloses methods for preparation of compoun...
|
|
WO/2022/002838A1 |
The invention relates to substituted heteroaryloxypyridines of the general formula (I) and to their use as herbicides, in particular for controlling weeds and/or weed grasses in crops of cultivated plants and/or as plant growth regulator...
|
|
WO/2022/001847A1 |
The present invention relates to a pharmaceutically acceptable salt of (S)-2-(6-fluorobenzo[d]oxazol-2-yl)-6-methoxy-5-((5-methoxyp
yridin-2-yl))methoxy)-1,2,3,4-tetrahydroisoquinoline-3-carbo
xylic acid, a preparation method therefor, a...
|
|
WO/2022/002142A1 |
The present application describes tetrahydroisoquinoline compounds as PRMT5 inhibitors and pharmaceutically acceptable salts thereof. Said compounds have the structure of formula (I), and have substituents and structural features describ...
|
|
WO/2022/002116A1 |
The present invention provides a synthesis method for a phenylisoxazoline compound, comprising: synthesizing uracil first by taking 2-fluoro-4-chloro-5-methylaniline as a starting raw material, and then synthesizing an isoxazoline ring t...
|
|
WO/2022/003557A1 |
The present invention relates to novel heterocyclic compounds of general formula (I) and their pharmaceutically acceptable salts, enantiomers and their diastereomers that are autotaxin (ATX) inhibitors. Compounds of general formula (I), ...
|
|
WO/2022/002078A1 |
The present invention relates to the fields of pharmaceutical chemistry and pharmacotherapeutics, and in particular to a compound as represented by general formula I, a racemate, an R-isomer, an S-isomer and a pharmaceutically acceptable...
|
|
WO/2022/002077A1 |
Disclosed in the present invention are an aryl aromatic heterocyclic derivative and preparation thereof and use thereof. The structure is as shown in formula I, and in this formula, the definitions of substituents are as stated in the de...
|
